HB Wealth Management LLC Sells 9,179 Shares of Zoetis Inc. $ZTS

HB Wealth Management LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 50.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 8,955 shares of the company’s stock after selling 9,179 shares during the quarter. HB Wealth Management LLC’s holdings in Zoetis were worth $1,127,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC raised its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the last quarter. Global Wealth Strategies & Associates bought a new position in shares of Zoetis during the fourth quarter worth about $25,000. Lodestone Wealth Management LLC bought a new position in shares of Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis during the third quarter worth about $31,000. Finally, Holos Integrated Wealth LLC bought a new position in shares of Zoetis during the fourth quarter worth about $32,000. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Bank of America raised their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $152.25.

Zoetis Trading Up 0.0%

Shares of ZTS stock opened at $116.92 on Monday. The company has a market cap of $49.18 billion, a P/E ratio of 19.42, a PEG ratio of 1.78 and a beta of 0.98. The stock has a 50 day simple moving average of $120.83 and a two-hundred day simple moving average of $125.28. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts forecast that Zoetis Inc. will post 7.02 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.